• Home
  • Blog
  • Issues
    • History of the FDA
    • Approval
    • Drug Development
    • Safety
    • Theory of Harm
    • FDA Incentives
    • Where Is the Market Failure Argument?
    • Medical Devices
    • Reform Options
    • Voluntary Provisions
    • Managing Risky Products
  • Publications
  • Features
    • Glossary
    • Links
    • Quotations
    • References
  • About
  • Donate
Search
  • Home
  • Blog
  • Issues
    • History of the FDA
    • Approval
    • Drug Development
    • Safety
    • Theory of Harm
    • FDA Incentives
    • Where Is the Market Failure Argument?
    • Medical Devices
    • Reform Options
    • Voluntary Provisions
    • Managing Risky Products
  • Publications
  • Features
    • Glossary
    • Links
    • Quotations
    • References
  • About
  • Donate
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
FDAReview.org
  • Home
  • Blog
  • Issues
    • History of the FDA
    • Approval
    • Drug Development
    • Safety
    • Theory of Harm
    • FDA Incentives
    • Where Is the Market Failure Argument?
    • Medical Devices
    • Reform Options
    • Voluntary Provisions
    • Managing Risky Products
  • Publications
  • Features
    • Glossary
    • Links
    • Quotations
    • References
  • About
  • Donate

Monthly Archives: March 2019

FDA Approves Ketamine-Based Drug to Treat Difficult Cases of Depression

Raymond March - March 28, 2019 0

Generic Insulin Now Available After Nearly One Hundred Years of Regulatory...

Raymond March - March 25, 2019 0

FDA Wants More Sunscreen Regulations, but Would Consumers Get Burned?

Raymond March - March 14, 2019 0

FDA Panel Backs Ketamine-Based Treatment for Depression

Raymond March - March 1, 2019 0
  • Home
  • Blog
  • Issues
    • History of the FDA
    • Approval
    • Drug Development
    • Safety
    • Theory of Harm
    • FDA Incentives
    • Where Is the Market Failure Argument?
    • Medical Devices
    • Reform Options
    • Voluntary Provisions
    • Managing Risky Products
  • Publications
  • Features
    • Glossary
    • Links
    • Quotations
    • References
  • About
  • Donate
© 2022 Independent Institute, 100 Swan Way, Oakland CA 94621-1428 | (510) 632‑1366.